scholarly journals Molecular Study of Glycoprotein (G) Gene Region of Rabies Virus from Spotted Deer, Delhi, India

2018 ◽  
Vol 50 (03) ◽  
pp. 28-35
Author(s):  
M Chhabra ◽  
2018 ◽  
Vol 73 ◽  
pp. 385
Author(s):  
G. Singh ◽  
R. Jaiswal ◽  
M. Chhabra ◽  
N.K. Gupta ◽  
M. Singhai ◽  
...  

2018 ◽  
Vol 44 ◽  
pp. S158
Author(s):  
A.M. Targovnik ◽  
G. Mc Callum ◽  
M.B. Arregui ◽  
L.F. Bracco ◽  
M. Micucci ◽  
...  

Viruses ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 218 ◽  
Author(s):  
Chunfu Li ◽  
Hongliang Zhang ◽  
Lina Ji ◽  
Xiao Wang ◽  
Yongjun Wen ◽  
...  

Previous studies have shown that wild-type (wt) rabies virus (RABV) evades the host immune response by restricting expression of glycoprotein (G), which blocks activation of dendritic cells (DCs) and induces production of virus-neutralizing antibodies (VNAs). In the present study, wt RABVs not only restricted G expression but also reduced incorporation of G into mature virions compared with laboratory-adapted viruses. A recombinant RABV expressing triple G was used to further determine whether G expression relates to incorporation. The recombinant virus showed higher expression and incorporation of G and activated more DCs than the virus that expressed a single copy of G. Removal of G from viruses using subtilisin or Dithiothreitol (DTT)/ Nonidet P-40 (NP40) almost completely abolishes DC activation and VNA production. Consequently, these G-depleted viruses cause lethal infection in mice. Thus, wt RABVs can subvert DC-induced antiviral immune response and maintain pathogenicity by decreasing G expression in infected cells and G incorporation into virions.


2000 ◽  
Vol 150 (3) ◽  
pp. 601-612 ◽  
Author(s):  
Yves Gaudin

Fusion of rabies virus with membranes is triggered at low pH and is mediated by the viral glycoprotein (G). The rabies virus-induced fusion pathway was studied by investigating the effects of exogenous lipids having various dynamic molecular shapes on the fusion process. Inverted cone-shaped lysophosphatidylcholines (LPCs) blocked fusion at a stage subsequent to fusion peptide insertion into the target membrane. Consistent with the stalk-hypothesis, LPC with shorter alkyl chains inhibited fusion at lower membrane concentrations and this inhibition was compensated by the presence of oleic acid. However, under suboptimal fusion conditions, short chain LPCs, which were translocated in the inner leaflet of the membranes, considerably reduced the lag time preceding membrane merging, resulting in faster kinetics of fusion. This indicated that the rate limiting step for fusion is the formation of a fusion pore in a diaphragm of restricted hemifusion. The previously described cold-stabilized prefusion complex was also characterized. This intermediate is at a well-advanced stage of the fusion process when the hemifusion diaphragm is destabilized, but lipid mixing is still restricted, probably by a ring-like complex of glycoproteins. I provide evidence that this state has a dynamic character and that its lipid organization can reverse back to two lipid bilayers.


2004 ◽  
Vol 48 (11) ◽  
pp. 853-864 ◽  
Author(s):  
Mai Sakai ◽  
Pushpa J. Kankanamge ◽  
Jun'ichi Shoji ◽  
Sanae Kawata ◽  
Tadafumi S. Tochikura ◽  
...  

2004 ◽  
Vol 78 (24) ◽  
pp. 13455-13459 ◽  
Author(s):  
Philip M. McKenna ◽  
Pyone Pyone Aye ◽  
Bernhard Dietzschold ◽  
David C. Montefiori ◽  
Louis N. Martin ◽  
...  

ABSTRACT Rabies virus (RV) has recently been developed as a novel vaccine candidate for human immunodeficiency virus type 1 (HIV-1). The RV glycoprotein (G) can be functionally replaced by HIV-1 envelope glycoprotein (Env) if the gp160 cytoplasmic domain (CD) of HIV-1 Env is replaced by that of RV G. Here, we describe a pilot study of the in vivo replication and immunogenicity of an RV with a deletion of G (ΔG) expressing a simian/human immunodeficiency virus SHIV89.6P Env ectodomain and transmembrane domain fused to the RV G CD (ΔG-89.6P-RVG) in a rhesus macaque. An animal vaccinated with ΔG-89.6P-RVG developed SHIV89.6P virus-neutralizing antibodies and SHIV89.6P-specific cellular immune responses after challenge with SHIV89.6P. There was no evidence of CD4+ T-cell loss, and plasma viremia was controlled to undetectable levels by 6 weeks postchallenge and has remained suppressed out to 22 weeks postchallenge.


Sign in / Sign up

Export Citation Format

Share Document